Search company, investor...

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Asset Sale | AssetsPurchased

Total Raised


About Proteus Digital Health

Proteus Digital Health is a digital medicine the measures medication treatment effectiveness and helps physicians improve clinical outcomes. It is comprised of ingestible sensors, a small wearable sensor patch, an application on a mobile device, and a provider portal. Once activated, Proteus unlocks never-before-seen insight into patient health patterns and medication treatment effectiveness, leading to more informed healthcare decisions

Proteus Digital Health Headquarters Location

2600 Bridge Parkway

Redwood City, California, 94065,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Proteus Digital Health

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Proteus Digital Health in 5 CB Insights research briefs, most recently on Jul 6, 2022.

Expert Collections containing Proteus Digital Health

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Proteus Digital Health is included in 11 Expert Collections, including Conference Exhibitors.


Conference Exhibitors

5,501 items

HLTH is a healthcare event bringing together startups and large companies from pharma, health insurance, business intelligence, and more to discuss the shifting landscape of healthcare


Pharma Supply Chain

1,258 items


Tech IPO Pipeline

568 items


Digital Health 150

150 items

2019's cohort of the most promising digital health startups transforming the healthcare industry


Sleep Health & Wellness

801 items

These companies aim to assess or improve the quantity/quality of sleep, or use sleep data in the monitoring or diagnosis of other health conditions.


Medical Devices

11,802 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

Proteus Digital Health Patents

Proteus Digital Health has filed 160 patents.

The 3 most popular patent topics include:

  • Radio electronics
  • Electronic circuits
  • Pharmaceutical industry
patents chart

Application Date

Grant Date


Related Topics




Molecular biology, Electrochemistry, Health informatics, Electronic test equipment, Electronic circuit simulators


Application Date


Grant Date



Related Topics

Molecular biology, Electrochemistry, Health informatics, Electronic test equipment, Electronic circuit simulators



Latest Proteus Digital Health News

Treatment setting, demographics impact adherence to biologic regimens for asthma care

Jun 9, 2022

Disclosures: Bosworth reports receiving research grants from beBetter, Boehringer Ingelheim, Improved Patient Outcomes, NIH, Novartis, Novo Nordisk, Otsuka, Proteus Digital Health, Sanofi, Veterans Administration and Walmart and consulting fees from Abbott, Boehringer Ingelheim, the Medicines Company, Otsuka, Preventric Diagnostics, Sanofi and Xcenda. Please see the study for all other authors’ relevant financial disclosures. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Please try again later. If you continue to have this issue please contact . Back to Healio Factors such as administration setting and demographics impacted adherence to biologic treatment among patients with moderate to severe asthma, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice. Although adherence rates were generally high overall, researchers found that treatment in a clinic setting and higher patient costs tended to lower adherence, whereas specialist access increased adherence. Hayden Bosworth, PhD, professor and vice chair for education with the department of population health sciences at Duke University School of Medicine, led stakeholders to better understand the relationship between asthma treatment and clinical inertia. “We identified six barriers to asthma treatment,” Bosworth told Healio. “An important barrier identified was patient/provider communication and the role of patient adherence and provider-appropriate treatment of asthma.” The study’s findings Using the Optum Clinformatics Data Mart database of commercially and publicly insured enrollees, the researchers examined the role of patient behaviors and factors on adherence among 3,932 patients with moderate to severe asthma treated with asthma biologics between Jan. 1, 2016, and April 30, 2020. Hayden Bosworth “Given the introduction of this new class of medications, we realized it would be beneficial to better understand patient adherence with these expensive medications,” Bosworth said. Researchers categorized patients based on whether they received treatment only in a clinic setting (n = 2,898), only at home (n = 786) or in a mixture of settings (n = 248). The patients in the clinic-only cohort were relatively younger on average with a higher proportion of men. They also tended to be white, from the Midwest and higher educated, and they reported higher household incomes, commercial insurance and mostly point-of-service health plan types compared with the other cohorts. Additionally, these patients had better overall health on average, with fewer comorbidities, other prior medications and health care use. The home and hybrid care patients, however, were relatively older, with at least 70% of them on Medicare insurance. They also had a higher burden of comorbidities and significantly higher patient costs for index biologics or all medications in the previous 6 months. The clinic-only patients had relatively lower adherence to their biologics treatment — calculated by dividing the number of observed biologic doses administered by the expected number of doses — (0.75; 95% CI, 0.5-1) compared with the home-only and hybrid cohorts (both, 0.83; 95% CI, 0.5-1). The researchers also found an association between 10-year increases in age and 1% (adjusted RR = 1.01; 05% CI, 1-1.03) higher biologic adherence rates among the clinic-only cohort. Additional factors associated with higher adherence in the clinic-only subgroup included a complex asthma regimen (aRR = 1.07; 95% CI, 1.03-1.11), any specialist visit during the previous 6 months (aRR = 1.08; 95% CI, 1.02-1.14) and comorbidities such as chronic sinusitis (aRR = 1.05; 95% CI, 1.01-1.09) and depression (aRR = 1.06; 95% CI, 1-1.12). Among the clinic-only group, the adherence rates of patients with a high school education or less were 5% (aRR = 0.95; 95% CI, 0.91-0.99) lower than those patients with less than a bachelor’s degree. Plus, patients in the clinic-only group whose household incomes were less than $40,000 a year had 5% (aRR = 1.05; 95% CI, 1-1.1) higher adherence rates compared with those with incomes between $40,000 and $99,000. Also, each $1,000 in patient costs for the index biologic in the clinic-only group appeared associated with a 2% (aRR = 0.98; 95% CI, 0.96-1) decrease in adherence rates. Researchers observed differences in adherence by race and ethnicity in the home subgroup, with 16% (aRR = 0.84; 95% CI, 0.72-0.99) lower adherence rates for Black patients and 13% (aRR = 0.87; 95% CI, 0.77-0.99) lower rates for Hispanic patients compared with white patients. Also in this group, patients with Medicare only had 26% (aRR = 0.74; 95% CI, 0.66-0.83) lower adherence rates than patients with commercial insurance. Yet patients in the home group who had seen any specialist in the previous 6 months (aRR = 1.14; 95% CI, 1-1.29) or who had a respiratory infection (aRR = 1.09; 95% CI, 1-1.18) had higher adherence. In the hybrid group, patients with unknown income had 19% (aRR = 1.19; 95% CI, 1.01-1.4) higher adherence rates compared with those with incomes between $40,000 and $99,000. Those with dementia had 33% (aRR = 0.67; 95% CI, 0.48-0.95) lower adherence. Implications of the results Overall, these trends reveal important factors affecting adherence that clinicians can consider. “While we confirmed that racial and ethnic disparities in medication adherence continue to be a problem, we think the finding that adherence varied by administration setting, with the clinic-only tending to have lower levels of adherence compared to at-home or hybrid administration, was important,” Bosworth said. Clinic-based care may have lower levels of adherence due to transportation barriers and potential implicit bias, as some people are offered clinic care instead of alternative administration, Bosworth explained. “This finding leads one to consider the importance of patient/provider shared decision-making on the preferred mode of administration,” he said. Also, a subspecialist visit in the 6 months before the onset of biologic therapy, the researchers wrote, corresponded with an 8% to 25% increase in adherence rates irrespective of the administration settings. This improved adherence with access to a specialist also was surprising, Bosworth said, leading the researchers to conclude that appropriate care coordination is necessary to ensure that patients with moderate to severe asthma get that access. The study offers several takeaways for doctors, Bosworth added. “The recognition and treatment of severe asthma continues to be problematic, but specialist access is important to ensure adequate use and adherence to these efficacious but expensive treatments,” Bosworth said. Better gateways and care coordination are necessary to ensure that patients with moderate to severe asthma who need further treatment get access to these medications, he continued. “Second, adherence is a problem, along with clinical inertia. But one solution may be better alignment of patient/provider preference for the location of administration of these treatments,” Bosworth said. Bosworth noted that clinicians can confidently prescribe biologics for at-home use in patients who are deemed capable of self-medicating, as the researchers found a positive association between home treatment and adherence. Meanwhile, the researchers also found that the barrier to adherence regardless of administration setting represented by patient financial burden highlights the need for policies and strategies to increase patient access to these therapies despite race or socioeconomic status. “Research focused on efforts to improve asthma biologic adherence are needed and should consider improving specialist access,” Bosworth said. “Research should also focus on better targeting patient subgroups with higher risk of suboptimal adherence.” For more information:

  • When was Proteus Digital Health founded?

    Proteus Digital Health was founded in 2001.

  • Where is Proteus Digital Health's headquarters?

    Proteus Digital Health's headquarters is located at 2600 Bridge Parkway, Redwood City.

  • What is Proteus Digital Health's latest funding round?

    Proteus Digital Health's latest funding round is Asset Sale.

  • How much did Proteus Digital Health raise?

    Proteus Digital Health raised a total of $509.3M.

  • Who are the investors of Proteus Digital Health?

    Investors of Proteus Digital Health include Otsuka Pharmaceutical, Paycheck Protection Program, Harbin Gloria Pharma, Silicon Valley Bank, Oxford Finance and 19 more.

  • Who are Proteus Digital Health's competitors?

    Competitors of Proteus Digital Health include MediSafe and 4 more.

You May Also Like


AiCure is an AI and advanced data analytics company targeting the health care industry. AiCure uses AI to see, hear and understand how people respond to treatment across clinical trials and patient care. Clinically proven to accurately measure and modify patient behavior, AiCure’s technologies keep patients engaged and optimized to treatment, as well as assess treatment effectiveness.

AdhereTech Logo

Digital Medical Technologies, dba AdhereTech, creates bottles that measure pills or liquid in real-time, wirelessly send this HIPAA-compliant data into the cloud, and remind patients to take their medication via automated phone call or text message.

Optimize Health Logo
Optimize Health

Optimize Health assists independent practices, group practices and ACOs, hospitals, partners, and health systems with remote patient monitoring, and engagement, client success, call center, and delivery services. The company was founded in 2015 and is based in Seattle, Washington.

MediSafe Logo

MediSafe helps people integrate healthier behavior into their daily lives with a cloud-synced mobile medication management system. It offers solutions, data insights, research, webinars, case studies and more. The company is founded in 2012 and is based in Haifa, Israel.


ConnectiveRx is a provider of patient access, prescription medication assistance solutions, and payment reimbursement services on behalf of pharmaceutical manufacturers. It is based in Whippany, New Jersey.

PerceptiMed Logo

PerceptiMed has developed a point-of-care product that provides real-time identification of individual pills and checks each pill against the patient's prescription. IdentRx identifies drug and dosage of individual pills, tablets and capsules in real-time. All prescription parameters are verified. Each prescription is checked for correct medication, dosage and quantity. Control of prescription delivery. Electonically-locked containers ensure medication delivered to correct patient.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.